{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:28:34Z","timestamp":1792168114737,"version":"4.4.0"},"reference-count":21,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2022,4,19]]},"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1136\/ejhpharm-2022-003297","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T13:33:21Z","timestamp":1653312801000},"page":"96-100","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["The role of clinical trials in the sustainability of the Italian national health service cancer drug expenditure"],"prefix":"10.1136","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6427-0809","authenticated-orcid":false,"given":"Lorenzo","family":"Gasperoni","sequence":"first","affiliation":[{"name":"Oncological Pharmacy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \"Dino Amadori\", Meldola, Emilia Romagna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Cafaro","sequence":"additional","affiliation":[{"name":"Oncological Pharmacy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \"Dino Amadori\", Meldola, Emilia Romagna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Ferretti","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy, Azienda USL Modena, Modena, Emilia-Romagna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Di Iorio","sequence":"additional","affiliation":[{"name":"Oncological Pharmacy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \"Dino Amadori\", Meldola, Emilia Romagna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana","family":"Nanni","sequence":"additional","affiliation":[{"name":"Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \"Dino Amadori\", Meldola, Emilia Romagna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8744-0708","authenticated-orcid":false,"given":"Carla","family":"Masini","sequence":"additional","affiliation":[{"name":"Oncological Pharmacy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \"Dino Amadori\", Meldola, Emilia Romagna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"2025090700165287000_30.2.96.1","unstructured":"International Association of Cancer Registries . The global cancer Observatory. Available: https:\/\/gco.iarc.fr\/today\/home [Accessed 1 mar 2021]."},{"key":"2025090700165287000_30.2.96.2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1130-6343(10)70003-9","article-title":"[Pharmacoeconomics and cost of cancer drugs]","volume":"34 Suppl 1","author":"Camps Herrero","year":"2010","journal-title":"Farm Hosp"},{"key":"2025090700165287000_30.2.96.3","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010814-124649"},{"key":"2025090700165287000_30.2.96.4","unstructured":"The Medicines Utilisation Monitoring Centre . National report on medicines use in Italy, 2019. Available: https:\/\/www.aifa.gov.it\/en\/-\/l-uso-dei-farmaci-in-italia-rapporto-osmed-2019 [Accessed 1 Mar 2021]."},{"key":"2025090700165287000_30.2.96.5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182613","article-title":"Addressing the challenge of high-priced prescription drugs in the era of precision medicine: a systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks","volume":"12","author":"Gronde","year":"2017","journal-title":"PLoS One"},{"key":"2025090700165287000_30.2.96.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.9746"},{"key":"2025090700165287000_30.2.96.7","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40273-017-0559-4","article-title":"The implementation of managed entry agreements in central and eastern Europe: findings and implications","volume":"35","author":"Ferrario","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"2025090700165287000_30.2.96.8","doi-asserted-by":"publisher","DOI":"10.1257\/jep.29.1.139"},{"key":"2025090700165287000_30.2.96.9","doi-asserted-by":"crossref","DOI":"10.3332\/ecancer.2018.823","article-title":"Risk-Sharing agreements, present and future","volume":"12","author":"Gon\u00e7alves","year":"2018","journal-title":"Ecancermedicalscience"},{"key":"2025090700165287000_30.2.96.10","unstructured":"The Medicines Utilisation Monitoring Centre . National report on medicines use in Italy, 2018. Available: https:\/\/www.aifa.gov.it\/en\/-\/rapporto-osmed-20-1 [Accessed 1 Mar 2021]."},{"key":"2025090700165287000_30.2.96.11","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-020-05928-6","article-title":"Clinical trials and drug cost savings for Italian health service","volume":"20","author":"D'Ambrosio","year":"2020","journal-title":"BMC Health Serv Res"},{"key":"2025090700165287000_30.2.96.12","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.495"},{"key":"2025090700165287000_30.2.96.13","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.acuro.2015.05.002","article-title":"Drug cost avoidance in prostate cancer clinical trials","volume":"39","author":"Calvin-Lamas","year":"2015","journal-title":"Actas Urol Esp"},{"key":"2025090700165287000_30.2.96.14","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1177\/1078155218775193","article-title":"Drug cost avoidance in clinical trials of breast cancer","volume":"25","author":"Ma\u00f1es-Sevilla","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"2025090700165287000_30.2.96.15","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.cct.2010.09.004","article-title":"Drug cost avoidance resulting from cancer clinical trials","volume":"31","author":"Bredin","year":"2010","journal-title":"Contemp Clin Trials"},{"key":"2025090700165287000_30.2.96.16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3747\/co.23.2861","article-title":"Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC clinical Trials Group phase III clinical trials in Canada","volume":"23","author":"Tang","year":"2016","journal-title":"Curr Oncol"},{"key":"2025090700165287000_30.2.96.17","unstructured":"Discipline of the therapeutic use of medicinal products subjected to clinical trials . Official Gazette of the Italian Republic general series n. 256 of 2, 2017."},{"key":"2025090700165287000_30.2.96.18","unstructured":"Determination n . DG 757\/2020 of 14 July 2020. Official Gazette of the Italian Republic general series n. 188 of 28, 2020."},{"key":"2025090700165287000_30.2.96.19","unstructured":"Italian Association for Medical Oncology (AIOM) . Breast neoplasms guidelines, 2020. Available: https:\/\/www.aiom.it\/linee-guida-aiom-2020-neoplasie-della-mammella\/ [Accessed 1 Mar 2021]."},{"key":"2025090700165287000_30.2.96.20","unstructured":"Italian Association of Medical Oncology (AIOM) . Early access in Italy. rules that define early access to anti-cancer drugs. scientific documents, 2019. Available: https:\/\/www.aiom.it\/early-access-in-italia-2\/ [Accessed 1 Mar 2021]."},{"key":"2025090700165287000_30.2.96.21","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-021-07255-w","article-title":"The economic impact of compassionate use of medicines","volume":"21","author":"Jommi","year":"2021","journal-title":"BMC Health Serv Res"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2022-003297","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T07:17:01Z","timestamp":1757229421000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2022-003297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,21]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1136\/ejhpharm-2022-003297"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2022-003297","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]}}}